Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines

Epidermal growth factor receptor (EGFR) is a well-validated oncological target molecule for monoclonal antibody therapies and Sym004 is a novel anti-EGFR antibody mixture comprising two recombinant chimeric IgG1 antibodies against non-overlapping epitopes of EGFR. Because EGFR is highly expressed in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Fukuoka, Shota, Kojima, Takashi, Koga, Yoshikatsu, Yamauchi, Mayumi, Komatsu, Masayuki, Komatsuzaki, Rie, Sasaki, Hiroki, Yasunaga, Masahiro, Matsumura, Yasuhiro, Doi, Toshihiko, Ohtsu, Atsushi
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355242/
https://ncbi.nlm.nih.gov/pubmed/28038457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14209
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares